A randomized, double-blind, placebo-controlled study of flexible doses of levomilnacipran ER (40–120 mg/day) in patients with major depressive disorder

Documenti analoghi

• A Randomized, Double-blind, Placebo-controlled Trial of the Efficacy and Safety of Levomilnacipran ER 40-120mg/day for Prevention of Relapse in Patients with Major Depressive Disorder
  di: Shiovitz, Thomas, et al.
  Pubblicazione: (2014)
• Levomilnacipran ER 40 mg and 80 mg in patients with major depressive disorder: a phase III, randomized, double-blind, fixed-dose, placebo-controlled study
  di: Bakish, David, et al.
  Pubblicazione: (2014)
• A Phase III, Double-Blind, Placebo-Controlled, Flexible-Dose Study of Levomilnacipran Extended-Release in Patients With Major Depressive Disorder
  di: Sambunaris, Angelo, et al.
  Pubblicazione: (2014)
• Efficacy of levomilnacipran extended-release in major depressive disorder: pooled analysis of 5 double-blind, placebo-controlled trials
  di: Montgomery, Stuart A., et al.
  Pubblicazione: (2014)
• Efficacy of levomilnacipran extended-release in improving functional impairment associated with major depressive disorder: pooled analyses of five double-blind, placebo-controlled trials
  di: Sambunaris, Angelo, et al.
  Pubblicazione: (2014)